Newsroom

PARIS--(BUSINESS WIRE)--Regulatory News: Xilam Films (Paris:ALXIL), filiale de Xilam Animation société indépendante de production et de distribution de programmes d’animation, nommée aux Oscars®, annonce la sélection officielle de son prochain long métrage familial Lucy Lost aux éditions 2026 du Festival de Cannes et du Festival international du film d’animation d’Annecy. Ce film est adapté du roman Listen to the Moon (2014) de Michael Morpurgo, célèbre écrivain britannique multiprimé. Il est d...

PARIS--(BUSINESS WIRE)--Regulatory News: Academy Award®-nominated French animation studio Xilam Films (Paris:ALXIL) has secured official selections for its upcoming family feature Lucy Lost, based on award-winning author and previous British Children’s Laureate Michael Morpurgo’s 2014 novel Listen to the Moon, at this year’s editions of the Cannes Film Festival and Annecy International Animation Film Festival. Additionally, through French distributor Le Pacte, the film is now set to release the...

NEW YORK--(BUSINESS WIRE)--Starboard Value LP (together with its affiliates, “Starboard”), one of the largest shareholders of Dynatrace, Inc. (“Dynatrace” or the “Company”) (NYSE: DT), today announced that it has delivered a letter to Dynatrace’s Chief Executive Officer, Rick McConnell, Chief Financial Officer, Jim Benson, and the Company’s Board of Directors. The full text of Starboard's letter to the Company can be viewed here. About Starboard Value LP Starboard Value LP is an investment advi...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 27.04.2026 UNCU.LN IE00BD6GCF16 801,374.00 USD 36,646,325.83 45.729  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 27.04.2026 UINC IE00BZBW4Z27 10,134,104.00 USD 385,818,499.89 38.071  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

NEW YORK--(BUSINESS WIRE)--Marsh (NYSE: MRSH), a global leader in risk, reinsurance and capital, people and investments and management consulting, today announced a multi-year partnership with the global sport of Formula 1® as the series’ first Official Risk Partner and Official Insurance Brokering Partner, marking a bold step as a unified, global brand. Anchored in Marsh's purpose—building the confidence to thrive through the power of perspective—the partnership reinforces a shared commitment...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that it will present new preclinical data on the company’s lead program AFTX-201, as well as highlight the design of the Phase 1/2 UPBEAT© clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopath...